本帖最后由 老马 于 2012-1-13 21:20 编辑
8 t* [8 u1 m# G8 }$ M7 s4 x5 Q2 o/ N+ w$ X6 y0 f" p7 P8 b+ N4 k5 i
爱必妥和阿瓦斯丁的比较: t! m/ z: b9 e9 Q& v2 o/ \4 S) |
5 {6 q5 s: r* V; H$ E- y. f1 bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 g* O' B' q1 A+ c. y6 @2 X5 I
: g; w3 N8 D& U4 X4 F# j; L
" U6 ~; F) }+ S4 ~7 mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, N5 p$ Z( G" B+ ~" c+ P! G% D==================================================! Y1 U0 W" D+ k6 L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 P9 D; ^' h- b
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: d C' q6 M5 }6 K7 {
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( { `7 [4 x9 s3 L* K6 O3 u
|